Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.

He R, Chen Y, Chen Y, Ougolkov AV, Zhang JS, Savoy DN, Billadeau DD, Kozikowski AP.

J Med Chem. 2010 Feb 11;53(3):1347-56. doi: 10.1021/jm901667k.

2.

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.

Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD, Kozikowski AP.

J Med Chem. 2009 Apr 9;52(7):1853-63. doi: 10.1021/jm801317h.

3.

Inhibition of glycogen synthase kinase-3.

Ougolkov AV, Billadeau DD.

Methods Mol Biol. 2008;468:67-75. doi: 10.1007/978-1-59745-249-6_5.

PMID:
19099246
4.

Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

Oppegard LM, Ougolkov AV, Luchini DN, Schoon RA, Goodell JR, Kaur H, Billadeau DD, Ferguson DM, Hiasa H.

Eur J Pharmacol. 2009 Jan 14;602(2-3):223-9. doi: 10.1016/j.ejphar.2008.11.044. Epub 2008 Dec 3.

5.

Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Ougolkov AV, Bilim VN, Billadeau DD.

Clin Cancer Res. 2008 Nov 1;14(21):6790-6. doi: 10.1158/1078-0432.CCR-08-1013.

6.

Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis.

Goodell JR, Ougolkov AV, Hiasa H, Kaur H, Remmel R, Billadeau DD, Ferguson DM.

J Med Chem. 2008 Jan 24;51(2):179-82. doi: 10.1021/jm701228e. Epub 2007 Dec 29.

PMID:
18163538
7.
8.

Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic beta-catenin activation.

Yamashita K, Ougolkov AV, Nakazato H, Ito K, Ohashi Y, Kitakata H, Yasumoto K, Omote K, Mai M, Takahashi Y, Minamoto T.

Dis Colon Rectum. 2007 Aug;50(8):1169-81. Erratum in: Dis Colon Rectum. 2007 Aug;50(8):1182-7.

PMID:
17347903
9.

Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.

Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD.

Clin Cancer Res. 2006 Sep 1;12(17):5074-81.

10.

Targeting GSK-3: a promising approach for cancer therapy?

Ougolkov AV, Billadeau DD.

Future Oncol. 2006 Feb;2(1):91-100. Review.

PMID:
16556076
11.

Oncogenic beta-catenin signaling networks in colorectal cancer.

Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T.

Cell Cycle. 2005 Nov;4(11):1522-39. Epub 2005 Dec 1. Review.

PMID:
16258275
12.

Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells.

Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD.

Cancer Res. 2005 Mar 15;65(6):2076-81.

13.

Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling.

Minamoto T, Ougolkov AV, Mai M.

Expert Rev Mol Diagn. 2002 Nov;2(6):565-75. Review.

PMID:
12465453
14.

Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer.

Ougolkov AV, Yamashita K, Mai M, Minamoto T.

Gastroenterology. 2002 Jan;122(1):60-71.

PMID:
11781281

Supplemental Content

Loading ...
Support Center